Lily L. Remsing Rix

This study identifies that CAFs confer ALK inhibitor resistance in EML4-ALK-driven lung cancer through both MET and integrin signaling pathways, and shows that targeting both pathways improves treatment efficacy.

This study shows that combining RET and SRC inhibitors enhances anti-cancer effects in RET fusion-positive cancers by suppressing PAK signaling and restoring sensitivity in resistant cells.